Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 11/20 | 0.59 |
| ▸ | CCR2 | P41597 | 2/20 | 0.54 |
| ▸ | CCR7 | P32248 | 1/20 | 0.54 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
| ▸ | CCR4 | P51679 | 1/20 | 0.52 |
| ▸ | RARB | P10826 | 7/20 | 0.49 |
| ▸ | RARA | P10276 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655515 | 0.95 | CCR5 (0.55) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3163964 | 0.95 | CCR5 (0.61) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3163971 | 0.95 | CCR5 (0.61) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3459367 | 0.94 | CCR5 (0.61) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3459366 | 0.94 | CCR5 (0.61) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3459362 | 0.94 | CCR5 (0.61) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL6343081 | 0.91 | CCR5 (0.60) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL5654599 | 0.91 | CCR5 (0.55) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3459703 | 0.90 | CCR5 (0.56) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3459699 | 0.90 | CCR5 (0.56) | CCR5CCR2CCR7CCR3CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-6936602-B1 | Benzazepine derivatives, process for the preparation of the same and uses thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-30 | — | — | US | disclosed |
| US-20050107606-A1 | Process for producing optically active sulfoxide derivative | TATKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1484322-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SULFOXIDE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| EP-1186604-A1 | BENZAZEPINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107606-A1 | Process for producing optically active sulfoxide derivative | CCR5, OPRM1, CXCR4 | CCR5 1/4885CCR2 5/4885CCR7 114/4885 |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | CCR5 2363/4885CCR2 1368/4885CCR7 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.